Subgroup Analysis of the MONALEESA-7 and-3 Studies at ASCO: Kisqali (R) from Novartis showed Overall Survival Benefit in HR+/HER2 advanced Breast Cancer with visceral Metastasis-MedSci.cn

Subgroup Analysis of the MONALEESA-7 and-3 Studies at ASCO: Kisqali (R) from Novartis showed Overall Survival Benefit in HR+/HER2 advanced Breast Cancer with visceral Metastasis

[Anonymous]

ONCOLOGY RESEARCH AND TREATMENT, 2020; 43 (7-8): 396

科室
- - 订阅+
  - 更多科室
工具
服务